Abstract 1247P
Background
Volatile organic compounds (VOCs) are known to be associated with lung cancer, and EGFR mutations are common in lung adenocarcinoma. In this study, we aimed to investigate the potential of VOCs analysis as a non-invasive method for early detection of EGFR mutation.
Methods
We collected breath samples from 114 EGFR wild-type lung adenocarcinoma patients and 132 EGFR mutant lung adenocarcinoma patients and analyzed them using High-Pressure Photon Ionization Time-of-Flight Mass Spectrometry (HPPl-TOFMS) to detect VOCs. A detection model for EGFR mutation based on VOC analysis was established using the eXtreme Gradient Boosting (XGB) algorithm. For building the EGFR mutation detection model, all the samples were randomly split into a training set, validation set, and test set with a ratio of 5:2:3.
Results
The top ten VOC ions which were significantly different between the EGFR mutant lung adenocarcinoma patients and patients without EGFR mutation were displayed in the table (P < 0.05). The discrimination power of each VOC was relatively limited. Among them, 2-Ethyl-4,5-dimethylthiazole had the highest accuracy with an area under the receiver operating characteristic curve (AUC) of 0.829 (95%CI: 0.744-0.974). With the combination of these 10 VOC ions, the model performs well. The AUC for the combination model was 0.895 (95% CI: 0.810-0.980) in the validation cohort, while the AUC in the test set was 0.849 (95% CI: 0.769-0.930), indicating good diagnostic accuracy, with sensitivity and specificity of 70.7% (95% CI: 56.6%, 84.4%) and 71.4% (95% CI: 56.2%, 86.6%). Table: 1247P
The top 10 VOC ions related to EGFR mutation in lung adenocarcinoma
Chemicals | Peak area | P-value | |
EGFR mut | RGFR wild | ||
Cyclohexanone oxime | 242.6±103.4 | 139.1±234.1 | <0.001 |
Dimethoxybenzene | 522.7±1730.2 | 200.0±256.6 | 0.017 |
Tert-Butyl methyl ether | 667.5±1655.3 | 278.4±302.0 | 0.006 |
2-Ethyl-4,5-dimethylthiazole | 659.0±1762.2 | 329.7±730.8 | 0.039 |
Trimethylbenzene | 375.1±617.7 | 202.9±185.6 | <0.001 |
Salicylamide | 310.6±332.9 | 203.0±187.3 | <0.001 |
p-cymene/Cinnamyl alcohol | 300.5±1002.5 | 123.5±130.7 | 0.038 |
L-serine/D-serine | 706.2±515.0 | 359.9±318.0 | <0.001 |
1-Propanethiol | 2005.3±1609.7 | 1419.7±1673.0 | 0.002 |
4-Methylanisole/2-Methylanisole | 402.1±314.4 | 180.1±220.1 | <0.001 |
Conclusions
Our study suggested that VOCs analysis might be useful as non-invasive methods for early detection of EGFR mutations in lung adenocarcinoma. Further studies are needed to validate the accuracy of our model.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Chinese National Natural Science Foundation Project; China Postdoctoral Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1229P - Selective phenotypic and genotypic evaluation of circulating glial cells for improved diagnosis of glial malignancies
Presenter: Sewanti Limaye
Session: Poster session 14
1230P - hPG80 (circulating progastrin) is a new blood-based biomarker for diagnosis of early-stage non-small cell lung cancers
Presenter: Paul Hofman
Session: Poster session 14
1231P - Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer
Presenter: Yeji Jung
Session: Poster session 14
1232P - Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification
Presenter: Xinrong Yang
Session: Poster session 14
1233P - Accurate prediction of gastrointestinal cancer tissue of origin using comprehensive plasma cell-free DNA fragmentomics features
Presenter: Xinrong Yang
Session: Poster session 14
1234P - HistoMate: Automated preprocessing software for digital histopathology image to enhance deep learning
Presenter: Jinok Lee
Session: Poster session 14
1235P - Enrichment of rare cancers in pragmatic precision cancer medicine trial: Experience from IMPRESS-Norway
Presenter: Aaslaug Helland
Session: Poster session 14
1236P - Feasibility of online symptom monitoring to detect lung cancer relapse in Poland
Presenter: Ewa Pawlowska
Session: Poster session 14
1237P - Design and validation of a custom next-generation sequencing panel in melanoma, glioma and gastrointestinal stromal tumor
Presenter: Xiaoyan Zhou
Session: Poster session 14
1238P - Detecting driver mutations by AmoyDx 11-gene PCR with high concordance with next-generation sequencing in Chinese non-small cell lung cancer patients
Presenter: Dongmei Lin
Session: Poster session 14